Innovative Stem Cell Transplant Eliminates Toxic Prep in Genetic Disease Treatment
Stanford Medicine researchers developed a safe and effective antibody-based method to perform stem cell transplants for genetic blood disorders without toxic chemotherapy or radiation, significantly improving patient outcomes.
A groundbreaking clinical trial conducted at Stanford Medicine has demonstrated that patients with genetic blood disorders can undergo stem cell transplants without the need for traditional toxic conditioning methods such as chemotherapy or radiation. Instead, researchers used a specialized antibody treatment that safely prepares patients by targeting and eliminating diseased blood-forming stem cells, significantly reducing risks associated with conventional procedures.
The study focused on children diagnosed with Fanconi anemia, a genetic condition impairing DNA repair, which makes standard transplants particularly risky due to heightened sensitivity to chemotherapy and radiation. In this trial, patients received an antibody called briquilimab, which targets CD117, a protein on blood stem cells. This approach allowed for the elimination of defective cells without the harmful side effects typically seen with traditional preparative regimens.
All three participating children successfully received transplants from their parents, with no incidents of rejection or graft-versus-host disease. Remarkably, the transplanted cells rapidly engrafted, and after two years, the patients' bone marrow was largely made up of donor cells, indicating successful and durable engraftment.
The significance of this advancement extends beyond Fanconi anemia. The new protocol opens avenues for safer transplants in patients with other genetic blood disorders and possibly in elderly or fragile cancer patients who are unable to tolerate aggressive conditioning. This innovative approach stems from decades of research on blood stem cell biology, especially the role of CD117, which was extensively studied at Stanford since 2004.
Dr. Agnieszka Czechowicz, a lead researcher, emphasized that this method not only reduces toxicity but also broadens access to life-saving transplants by allowing for donations from less perfectly matched donors. The success of this trial paves the way for larger studies and potential expansion to treat various other conditions, promising a safer, more accessible future for stem cell therapy.
Source: https://medicalxpress.com/news/2025-07-stem-cell-transplant-toxic-successfully.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Biodegradable Scaffold Accelerates Bone Healing and Regeneration
A novel biodegradable scaffold developed by Penn State researchers significantly enhances bone healing by delivering nutrients directly to injury sites, promising faster and more effective regenerative treatments.
Patient-Delivered Care Shows Promise for Sustaining Weight Loss Better Than Traditional Professional Programs
New research suggests that patient-delivered support models may outperform traditional professional programs in sustaining weight loss, offering a sustainable and cost-effective approach to long-term obesity management.
Emerging Potential of CAR-T Therapy as a Cure for Lupus: Insights from Early Trials
Early clinical trials of CAR-T therapy show promising results in treating severe lupus cases, offering hope for a potential cure for this complex autoimmune disease.
Majority of Children with Pediatric Asthma Meet Diagnostic Guidelines
A new study reveals that around 60% of children diagnosed with asthma meet international guideline criteria, emphasizing the importance of objective testing for accurate diagnosis and treatment.